Navigation Links
EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models

R. Bray, Ph.D., Vice President, Research at EntreMed, commented on the presentations, "Results from these preclinical studies highlight the tremendous progress we have made with this compound and further support our selection of ENMD-981693 as the lead for our Aurora kinase program. ENMD-981693 has been shown to induce tumor regression in multiple preclinical models, which demonstrates the compound's potential clinical utility in a broad variety of cancers. IND-directed studies are currently underway and we anticipate the filing of an IND for ENMD-981693 in the fourth quarter of 2007."

To view the presentations, visit the Recent Presentations section of the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in multiple Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, an oral cell-cycle regulator, is in various Phase 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for fu
'"/>




Page: 1 2 3

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
4. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
5. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
6. AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer
7. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
Post Your Comments:
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Tobramycin Market, 2010-2019" ... traditional antibiotic whose eye drop and ointment are the ... infection or inflammation caused by eye infection. Currently, dozens ... able to produce tobramycin, among which the Top 5 ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Developed by ... selective prostaglandin receptor agonist which effectively reduces intraocular ... by FDA, latanoprost (under the trade name of ...
(Date:8/28/2015)... 2015  Perrigo Company plc ("Perrigo") (NYSE: PRGO ... acquisition of leading OTC brands from GSK in an ... is a clear demonstration of Perrigo,s unique ability to ... network spanning 36 countries.  Perrigo Chairman, ... "We are excited to complete this transaction, which clearly ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... PharMEDium Healthcare Corporation has become an Industry Supporter of ... of a new Corporate Supporter program available to pharmaceutical, ... N. Jonas, PharMEDium Chairman and CEO commented, "We are ... field through leadership, education and research.  As a leading ...
... FAIRFAX, Va., April 11, 2011 General Dynamics ... (NYSE: GD ), has been awarded ... training instrumentation suite into the Vincennes University hospital ... a realistic training environment for the continuing education ...
Cached Medicine Technology:PharMEDium Becomes a Corporate Supporter of the American Society of Anesthesiologists (ASA) 2General Dynamics' InForce™ Training Toolkit to Support Vincennes University Hospital Simulation Lab 2
(Date:8/29/2015)... ... 2015 , ... Targeted therapies, made possible by a growing ... according to a newly published report. Surviving Mesothelioma has more on the findings ... The authors of the new paper focus on several types of targeted approaches ...
(Date:8/29/2015)... ... 2015 , ... People who have heart or lung diseases, ... are at higher risk from wildfire smoke especially in Calgary, Alberta.Those with existing ... (arrhythmia or irregular heartbeat) are also sensitive to air pollution. , Tiny ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Decatur County Memorial Hospital recently transitioned management companies to partner with Wound Care ... for their outpatient wound center. , Transitioning wound care management providers can ...
(Date:8/28/2015)... ... ... With the goal of furthering music education programs in schools, the “Music ... Fairgrounds in Mendon, IL on May 30th, 2015. Backed once again by Best Drug ... underfunded school districts of Mendon and its neighboring town of Quincy, IL. Best Drug ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... On May ... Michigan, joined as sponsor of the “Music With A Mission” benefit concert in Mendon, ... the event was to raise money to support music education programs in the underfunded ...
Breaking Medicine News(10 mins):Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... A Danish study had reported that children in their teens ... to the harsh glare of the sun. // In the ... researchers had asked 340 volunteers to wear a wristwatch that ... UVR doses. ,The volunteers of the study included ...
... and Japan have been able to identify a type ... //beings awake. By tracking the nerve cells in rats, ... neuron receives inhibitory signals during night that makes them ... a chemical called orexin that keeps the animal awake. ...
... that increased exposure to infections in early infancy, as ... of developing acute lymphoblastic leukemia. ,The study results ... UK of age 2 to 14 yrs without cancer ... acute lymphoblastic leukemia. Day care and social activities were ...
... Medical School said that intake of calcium supplements over ... people at risk of colon cancer.// ,Calcium ... pre-cancerous polyp formations in colon. Calcium has chemo protective ... ,The previous study was in a trial, which ...
... Athletes who drink water during long distance running events ... much water // is almost as bad for health ... says the study researchers of UT Southwestern Medical Center, ... long race may lead to a condition called hyponatremia. ...
... have found out that having green tea catechins for a ... in males.// ,Of the 32 people who were ... only one person developed the cancer. They all had been ... the property of green tea catechins or a component of ...
Cached Medicine News:
Knowles Pins are available in 9" (228mm) overall length with 9/64" (3.5mm) shaft diameter and 1/4" (6.4mm) square bead....
... Calibrated Guide Wires are available in two ... 9 in. length. Material: DePuy certified stainless ... ,Smooth wires etched in 1/2 in. ... also available. Etched in 1/2 in. ...
Kirschner Wires are available in four point styles ranging from .028 to .062 in. Smooth tip wire available in 4, 6 and 9 in. lengths. Threaded tip available. Material: DePuy certified stainless steel...
... Non-Donor Supplemental: Calypte Biomedical ... HIV-1 antibody testing algorithm as well ... Western Blot Kit [Human Immunodeficiency Virus ... products represent a portfolio of established ...
Medicine Products: